Clinical evaluation is a fundamental regulatory requirement for Software as a Medical Device (SaMD), directly impacting its market approval and real-world application. It serves as the mechanism by which developers demonstrate that their software delivers the intended clinical benefits and performs safely across its intended use cases.
Unlike traditional hardware medical devices, SaMD lacks a physical component, so its safety and performance must be proven through evidence-based data — from literature, clinical performance evaluations, and real-world use. Without a robust clinical evaluation, regulatory clearance and post-market acceptance become unlikely.
Clinical evaluation for SaMD refers to the systematic collection and analysis of clinical data to verify that the software achieves its intended medical purpose, consistently and safely. It is required by regulators to demonstrate that the software’s clinical benefits outweigh its potential risks.
Unlike traditional devices where physical mechanisms can be directly tested or visualized, SaMD relies on algorithms, data inputs, and user interaction. Therefore, its evaluation often includes not only bench testing or simulations, but also analysis of published literature, clinical case studies, and usability validation.
The evaluation may involve real-world evidence, such as retrospective studies, registries, or performance metrics from software in active use. In many cases, this may supplement or substitute for formal clinical investigations — especially for lower-risk classes.
Clinical evaluation is mandated by several global regulatory frameworks:
Under Annex XIV, SaMD must undergo clinical evaluation as part of the conformity assessment process. The evaluation should include a Clinical Evaluation Plan (CEP), and eventually feed into the Clinical Evaluation Report (CER).
While terminology differs, clinical evaluation in the US context includes clinical validation, typically required in 510(k) or De Novo submissions. Demonstrating safety and effectiveness through relevant data is critical.
Provides a harmonized structure for clinical evaluation of SaMD. It distinguishes between clinical association, analytical validation, and clinical validation.
The depth and extent of the evaluation depend heavily on the risk classification of the SaMD. Higher-risk devices (e.g., diagnostic or therapeutic software) demand stronger clinical evidence and possibly prospective clinical studies. Lower-risk tools may rely more on literature and real-world performance data.
Clinical Evaluation Plan (CEP)
This foundational document outlines how the clinical evaluation will be conducted. It includes objectives, target population, intended use, evaluation methodology, and sources of data.
Clinical Evidence
This includes all data demonstrating that the software performs safely and delivers clinical benefit. Sources may include clinical studies, post-market data, and comparative performance reports.
Literature Review vs. Clinical Investigation
For low- and medium-risk SaMDs, systematic literature reviews may suffice if the evidence is relevant and recent. However, for novel software or high-risk tools, clinical investigations (prospective or retrospective) may be necessary.
Benefit-Risk Analysis
This part of the evaluation analyzes whether the clinical benefits of using the SaMD outweigh the potential risks under real-world conditions. This must be evidence-backed and clearly aligned with the intended use.
Clinical evaluation relies on a diverse set of data sources:
Peer-reviewed studies demonstrating clinical effectiveness of similar software or algorithms. Must be critically appraised and justified as relevant.
Analytical performance studies showing sensitivity, specificity, accuracy, and reproducibility.
Post-market surveillance data, user feedback, registry data, and health outcomes gathered from active software usage.
Using a combination of these sources strengthens the evaluation and supports robust regulatory submissions.
Early planning is key. Teams should begin developing the CEP and gathering evidence in parallel with software development — not as an afterthought. Clinical relevance must be embedded in the development lifecycle.
Common pitfalls include:
For startups or AI-driven SaMDs, challenges are even more pronounced. These products often evolve quickly, and their algorithms may change based on new data. This creates a moving target for validation and evaluation.
Best practices:
Clinical evaluation is not just a regulatory checkbox — it’s a safety net. For SaMD, it provides the framework to demonstrate that a purely digital product has real-world clinical value. When done right, it accelerates approval, increases user trust, and reduces the risk of harm.
At Pharmaxi, we combine deep expertise in software development with clinical and regulatory knowledge. Whether you’re a startup developing an AI-based diagnostic app or a manufacturer scaling a CE-marked product, our team can guide you through the entire clinical evaluation process.
👉 Need help with SaMD clinical evaluation? Contact our regulatory experts to ensure your documentation meets international standards.
Contact us
